We have recently demonstrated that inhibitors of the MDM2-dependent degradation of p53 exert anti-cancer effects also in the cells carrying these mutations [11], suggesting that in the absence of the transcriptional activity, the mitochondrial apoptotic pathway induced by p53 is still active [11]. This evidence concerns the gene TP53 and cancer.